STRATA Skin Sciences Inc. (SSKN)’s Financial Results Comparing With LeMaitre Vascular Inc. (NASDAQ:LMAT)

Both STRATA Skin Sciences Inc. (NASDAQ:SSKN) and LeMaitre Vascular Inc. (NASDAQ:LMAT) compete on a level playing field in the Medical Instruments & Supplies industry. We will evaluate their performance with regards to institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
STRATA Skin Sciences Inc. 2 -0.83 11.84M 5.10 0.54
LeMaitre Vascular Inc. 35 -22.27 16.39M 0.91 36.24

Table 1 shows gross revenue, earnings per share and valuation of the two companies. LeMaitre Vascular Inc. has lower earnings, but higher revenue than STRATA Skin Sciences Inc. The business that is more affordable between the two has a lower P/E ratio. STRATA Skin Sciences Inc. is presently more affordable than LeMaitre Vascular Inc., because it’s trading at a lower P/E ratio.

Profitability

Table 2 hightlights the net margins, return on equity and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
STRATA Skin Sciences Inc. 493,210,030.83% -20.6% -13.4%
LeMaitre Vascular Inc. 47,206,221.20% 18% 15.4%

Volatility and Risk

A beta of 1.42 shows that STRATA Skin Sciences Inc. is 42.00% more volatile than Standard & Poor’s 500. Competitively, LeMaitre Vascular Inc.’s 16.00% volatility makes it more volatile than Standard & Poor’s 500, because of the 1.16 beta.

Liquidity

The Current Ratio of STRATA Skin Sciences Inc. is 4.5 while its Quick Ratio stands at 4. The Current Ratio of rival LeMaitre Vascular Inc. is 4.9 and its Quick Ratio is has 3.5. LeMaitre Vascular Inc. is better equipped to clear short and long-term obligations than STRATA Skin Sciences Inc.

Analyst Recommendations

The Recommendations and Ratings for STRATA Skin Sciences Inc. and LeMaitre Vascular Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
STRATA Skin Sciences Inc. 0 0 1 3.00
LeMaitre Vascular Inc. 0 1 2 2.67

STRATA Skin Sciences Inc.’s upside potential is 199.15% at a $7 average target price. Meanwhile, LeMaitre Vascular Inc.’s average target price is $38.67, while its potential upside is 7.45%. Based on the analysts belief we can conclude, STRATA Skin Sciences Inc. is looking more favorable than LeMaitre Vascular Inc.

Insider and Institutional Ownership

STRATA Skin Sciences Inc. and LeMaitre Vascular Inc. has shares owned by institutional investors as follows: 75.8% and 80.2%. STRATA Skin Sciences Inc.’s share owned by insiders are 1.38%. Comparatively, insiders own roughly 17.6% of LeMaitre Vascular Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
STRATA Skin Sciences Inc. 9.96% 13.11% 3.76% -5.48% 33.98% 6.15%
LeMaitre Vascular Inc. -0.93% 18.05% 13.17% 39.27% -4.14% 39.97%

For the past year STRATA Skin Sciences Inc.’s stock price has smaller growth than LeMaitre Vascular Inc.

Summary

On 9 of the 15 factors LeMaitre Vascular Inc. beats STRATA Skin Sciences Inc.

STRATA Skin Sciences, Inc., a medical technology company, engages in developing and commercializing products for the treatment of dermatological disorders. Its products include XTRAC and VTRAC devices used for the treatment of psoriasis, vitiligo, and other skin disorders; and MelaFind system, an instrument for aiding dermatologists in the evaluation of clinically atypical pigmented skin lesions, when a dermatologist chooses to obtain additional information before making a final decision to biopsy in order to rule out melanoma. The company was formerly known as MELA Sciences, Inc. and changed its name to STRATA Skin Sciences, Inc. in December 2015. STRATA Skin Sciences, Inc. was founded in 1989 and is based in Horsham, Pennsylvania.

LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company provides angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; carotid shunts to temporarily divert or shut blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and powered phlebectomy devices that enable removal of varicose veins. It also offers embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude blood flow; and perfusion catheters that temporarily perfuse blood and other liquids into the vasculature. In addition, the company provides radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patientÂ’s body, and allows them to locate tributaries or lesions beneath the skin; and remote endarterectomy devices to remove plaque from arteries in the leg. Further, it offers valvulotomes that cuts valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; vascular grafts to bypass or replace diseased arteries; vascular patches, which are used for precision endarterectomy vascular reconstruction; vessel closure systems to attach vessels to one another with titanium clips instead of sutures; and laparoscopic cholecystectomy devices to inject dye into the cystic duct during laparoscopic cholecystectomy, as well as laparoscopic accessory for use in laparoscopic gall bladder removal. LeMaitre Vascular, Inc. markets its products through direct and indirect sales force. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was founded in 1983 and is headquartered in Burlington, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.